{"DataElement":{"publicId":"7751477","version":"1","preferredName":"Melanoma Number of Known Primary Tumors at Initial Diagnosis Count","preferredDefinition":"The quantity of known primary tumors at the time of the initial melanoma diagnosis.","longName":"7751476v1.0:6272433v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7751476","version":"1","preferredName":"Melanoma Number of Known Primary Tumors at Initial Diagnosis","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain._A request to indicate the number of known primaries at the time of the melanoma diagnosis.","longName":"3108463v1.0:7751474v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"3108463","version":"1","preferredName":"Melanoma","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes that contain melanin.  Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma.  Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi.  Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system.  Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain. -- 2004","longName":"C3224","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melanoma","conceptCode":"C3224","definition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"888ED2DC-38AD-7A5E-E040-BB89AD4317F2","latestVersionIndicator":"Yes","beginDate":"2010-06-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-08","modifiedBy":"ONEDATA","dateModified":"2010-06-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7751474","version":"1","preferredName":"Number of Known Primaries at the Time of Initial Melanoma Diagnosis","preferredDefinition":"A request to indicate the number of known primaries at the time of the melanoma diagnosis.","longName":"C158640","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Number of Known Primaries at the Time of Initial Melanoma Diagnosis","conceptCode":"C158640","definition":"A request to indicate the number of known primaries at the time of the melanoma diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"C820CFF4-8A07-1220-E053-4EBD850AC942","latestVersionIndicator":"Yes","beginDate":"2021-07-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-27","modifiedBy":"ONEDATA","dateModified":"2021-07-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C820CFF4-8A18-1220-E053-4EBD850AC942","latestVersionIndicator":"Yes","beginDate":"2021-07-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-27","modifiedBy":"ONEDATA","dateModified":"2021-07-27","changeDescription":"7/27/21 jk added Phase 3 CM Baseline CSI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6272433","version":"1","preferredName":"Count","preferredDefinition":"To determine the number or amount of something; the result of this activity.","longName":"6272433v1.0","context":"CCTG","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008541","version":"1","preferredName":"Numbers","preferredDefinition":"the set of non-negative integers.","longName":"NUMS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227CE66-2830-4A7B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2261845","version":"1","preferredName":"Count","preferredDefinition":"To determine the number or amount of something; the result of this activity.","longName":"C25463","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Count","conceptCode":"C25463","definition":"Determining the number or amount of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FBB87F7A-646B-1AFC-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-13","modifiedBy":"ONEDATA","dateModified":"2005-07-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCTG: Canadian Cancer Trials Group","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BDD425C-ADB5-4AA0-E053-F662850AB2B1","latestVersionIndicator":"Yes","beginDate":"2018-05-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-10","modifiedBy":"TAYLORT","dateModified":"2018-11-26","changeDescription":"11/26/18 TT released/CWinch. 5/10/18 tt/MA39.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"10000348","version":"1","longName":"Melanoma","context":"OCCPR"},{"publicId":"7634324","version":"1","longName":"CM Baseline","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Number of known primaries at","type":"Preferred Question Text","description":"Number of known primaries at the time of initial melanoma diagnosis","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"C81BC49A-9A80-3B4B-E053-4EBD850ABE3E","latestVersionIndicator":"Yes","beginDate":"2021-07-27","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2021-07-27","modifiedBy":"KNABLEJ","dateModified":"2021-07-27","changeDescription":"7/27/21 jk created for Phase 3 CM Baseline CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}